[The treatment of choice in deep vein thrombosis of the lower extremity].
Of 67 patients with acute deep vein thrombosis of the lower extremity (DVT), 43 patients were treated by venous thrombectomy and 24 patients were managed by conservative treatment. The clinical effect of thrombectomy was evaluated by analyzing follow-up results in the 2 groups. The cumulative incidences of pigmentation and stasis ulcer at the 5th year were 2.7% and 0% respectively in the thrombectomy group, and 24.3% and 10% respectively in the conservative treatment group. Pigmentation and stasis ulcer were significantly more frequent in the conservative treatment group (p < 0.01). It is concluded that venous thrombectomy is superior to conservative treatment to prevent late postthrombotic sequelae. Protein C, protein S and plasminogen were assayed in 40 DVT patients to determine the incidence of hypercoagulable state in DVT. Congenital deficiency or abnormality were found in 15 patients (37.5%). In such DVT patients with thrombophilia anticoagulant prophylaxis should be continued to decrease a risk of rethrombosis.
Sakurai
T
T
First Department of Surgery, Nagoya University School of Medicine, Japan.
Maki
A
A
Nishikimi
N
N
Ikezawa
T
T
Yano
T
T
Takamatsu
J
J
Kagami
K
K
D000328:Adult; D000368:Aged; D003020:Clothing; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000172:deficiency; D020151:Protein C Deficiency; D018455:Protein S Deficiency; D017131:Thrombectomy; D013924:Thrombophlebitis / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D014859:Warfarin / Q000627:therapeutic use
D014859:Warfarin; D010958:Plasminogen; D006493:Heparin; D014568:Urokinase-Type Plasminogen Activator